Quarterly ResultAug 11, 2026, 04:01 PM
Taysha Completes TSHA-102 Dosing; Raises $230M; Q2 Net Loss $46.6M
AI Summary
Taysha Gene Therapies reported Q2 2026 financial results and provided a corporate update, highlighting the completion of dosing in its pivotal REVEAL (N=17) and ASPIRE (N=4) trials for TSHA-102 in Rett syndrome. The company expects to report topline data from the 6-month interim analysis and receive FDA feedback on the BLA submission pathway in the first half of 2027. TSHA-102 continues to demonstrate a generally well-tolerated safety profile across all trials. Taysha also completed a $230 million follow-on offering, extending its cash runway into the second half of 2028 and through potential BLA approval, while advancing commercial readiness activities.
Key Highlights
- Completed dosing in REVEAL pivotal (N=17) and ASPIRE (N=4) trials for TSHA-102.
- Topline data from 6-month interim analysis and FDA feedback on BLA pathway expected in 1H 2027.
- TSHA-102 was generally well tolerated with no severe treatment-related SAEs or DLTs across trials (N=33).
- Completed a $230 million follow-on offering, extending cash runway into 2H 2028.
- Q2 2026 R&D expenses increased to $38.6 million from $20.1 million YoY.
- Q2 2026 net loss was $46.6 million, or $0.13 per share.
- Cash and cash equivalents stood at $455.4 million as of June 30, 2026.
- Expanded strategic partnership with Catalent for TSHA-102 commercial manufacturing.
Price Impact
More from TSHA